Fulvaa 250 mg Prefilled Syringe Injection 5 ml belongs to the class of estrogen blockers used to treat breast cancer in postmenopausal women. Breast cancer is a type of cancer that develops when the breast cells begin to grow abnormally.

Fulvaa 250 mg Prefilled Syringe Injection 5 ml contains Fulvestrant, which works by inhibiting some of the actions of estrogen (female sex hormone which may help cancer cells grow in women with breast cancer) and reducing the amount that is in the body. Thus, it helps in reducing breast cancer tumour growth.

Fulvaa 250 mg Prefilled Syringe Injection 5 ml will be administered by a healthcare professional; do not self-administer. In some cases, Fulvaa 250 mg Prefilled Syringe Injection 5 ml may cause certain common side effects such as injection site reactions like pain and/or inflammation, weakness, nausea, tiredness, headache or joint and musculoskeletal pain. Most of these side effects of Fulvaa 250 mg Prefilled Syringe Injection 5 ml do not require medical attention and gradually resolve over time. However, if these side effects persist or worsen, please consult your doctor.

If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Fulvaa 250 mg Prefilled Syringe Injection 5 ml is not recommended for pregnant women as it may harm an unborn baby. Fulvaa 250 mg Prefilled Syringe Injection 5 ml is contraindicated for use during lactation. Avoid alcohol consumption while receiving Fulvaa 250 mg Prefilled Syringe Injection 5 ml. Avoid driving or operating machinery if you feel tired or weak after receiving Fulvaa 250 mg Prefilled Syringe Injection 5 ml.

Fulvaa 250 mg Prefilled Syringe Injection 5 ml contains Fulvestrant, used to treat breast cancer in postmenopausal women. Additionally, Fulvaa 250 mg Prefilled Syringe Injection 5 ml may be used in combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or has spread to other parts of the body (metastatic).

If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Fulvaa 250 mg Prefilled Syringe Injection 5 ml is not recommended for pregnant women as it may harm an unborn baby. Using effective contraception while being treated with Fulvaa 250 mg Prefilled Syringe Injection 5 ml and for two years after the last dose is advised. Fulvaa 250 mg Prefilled Syringe Injection 5 ml is contraindicated for use during lactation. Avoid alcohol consumption while receiving Fulvaa 250 mg Prefilled Syringe Injection 5 ml. Avoid driving or operating machinery if you feel tired or weak after receiving Fulvaa 250 mg Prefilled Syringe Injection 5 ml.